Sarah Isabel Sheikh talks to Neurodegenerative Disease Management about her research into the development of neuroregenerative-based therapies for multiple sclerosis.
Browsing: Demyelinating disease
In this interview from Neurodegenerative Disease Management, hear from Shibeshih Belachew (Roche) on the future of multiple sclerosis trials and therapeutics.
Researchers have discovered that a simple blood test to detect a nerve protein, neurofilament light chain, may be an efficient way to monitor symptoms in patients with relapsing-remitting MS.
Although exercise training has been advocated as a nonpharmacological treatment for multiple sclerosis-related fatigue, no consensus exists regarding its effectiveness.
Researchers have demonstrated significant reductions in levels of fatigue for multiple sclerosis patients in a randomized trial assessing transcranial direct current stimulation.
A collaboration of researchers from across the USA has uncovered two closely related cytokines that may help explain why certain patients develop progressive multiple sclerosis, the most severe form of the disease.
Novel research has suggested the gut microbiome is involved in multiple sclerosis and could be a treatment target.
Luciano Rossetti discusses the recent European Commission cladribine approval, as well as the current outlook for the multiple sclerosis drug pipeline.
Researchers discover latent human herpes virus 6 may interfere with the brains ability to repair damaged myelin in brain diseases such as multiple sclerosis.
Today marks World MS Day, a day to bring the global MS community together to raise awareness, celebrate pioneering research, and look ahead to the future.